BioCentury | Mar 16, 2021
Deals

March 15 Quick Takes: Canada’s CPP leads insitro’s $400M series C; plus Bicara, Aveo, Gilead-Merck and more

...that no longer respond to standard-of-care treatments. Its CEO, Claire Mazumdar, has prior experience at Rheos Medicines Inc....
BioCentury | Jan 8, 2020
Company News

Management tracks: Fred Hutch taps BMS CSO Lynch; plus GSK, Rubius, Provention, Antengene, Revitope, Compugen, Wellington, Adamas, Arcturus and Turnstone

...hired Laurence Turka as CSO, a new position. He co-founded and served as CSO of Rheos Medicines Inc....
BioCentury | Jan 4, 2020
Emerging Company Profile

Rheos: applying immune cell reprogramming to autoimmunity

...to attract its first major deal less than two years after launch. On Dec. 19, Rheos Medicines Inc....
...to systematically uncover the physiological links between metabolism of immune cells and disease.” Lauren Martz, Senior Editor Rheos Medicines Inc. AutoImmune...
BioCentury | Dec 19, 2019
Company News

Rheos spins immunometabolism platform into deal with Roche

...the partners may share worldwide development and U.S. commercialization rights to certain products. Lauren Martz, Associate Editor Rheos Medicines Inc. AutoImmune...
BioCentury | Oct 23, 2019
Company News

Management tracks: Amgen’s Meline retiring; plus BlackThorn, Rheos, Novartis, Kintai, Myriad, Avrobio, Oncorus, Moberg, Achilles and Aerpio

...Inc. (NASDAQ:TBPH). BlackThorn is a computational sciences company developing therapies for neurobehavioral disorders. Immunometabolism company Rheos Medicines Inc....
...ocular disease company has begun to explore strategic alternatives, including a possible sale. BioCentury Staff BlackThorn Therapeutics Inc. Rheos Medicines Inc. Kintai...
BioCentury | Oct 10, 2018
Company News

Management tracks: Hamburg joins Alnylam board

...Curatolo was head of commercial U.S. at NLS Pharma Group (Stans, Switzerland). Cellular metabolism company Rheos Medicines Inc....
BioCentury | Sep 6, 2018
Company News

Management tracks: Rheos, Aileron

...Immunometabolism company Rheos Medicines Inc. (Cambridge, Mass.) hired Sanjay Keswani as CEO. He was SVP and global head...
BioCentury | Apr 26, 2018
Targets & Mechanisms

Raising metabolism

...Management to develop glutamine antagonists to treat cancer. Two days later, Third Rock Ventures brought Rheos Medicines Inc....
...Ecto-5'-nucleotidase (CD73; NT5E) Preclin Ideaya Biosciences Inc. IDO Aryl hydrocarbon receptor (AHR) Preclin $140 2015 Rheos Medicines Inc....
...NASDAQ:INCY), Wilmington, Del. Kyn Therapeutics Inc., Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Rheos Medicines Inc....
BioCentury | Mar 23, 2018
Financial News

Third Rock launches immuno-metabolism company Rheos

...Immuno-metabolism company Rheos Medicines Inc. (Cambridge, Mass.) emerged from stealth mode with a $60 million series A round...
...transcriptional and metabolomic profiling data sets derived from human immune cell samples. Rheos Medicines Inc., Cambridge, Mass. Chris Lieu Rheos Medicines Inc....
BioCentury | Mar 22, 2018
Finance

Immune precision

...Third Rock Ventures is taking a page from cancer and Orphan diseases by launching Rheos Medicines Inc. to...
...of its companies when they go public (see BioCentury, Jan. 25, 2016) . Chris Lieu, Staff Writer Rheos Medicines Inc. Third...
Items per page:
1 - 10 of 11
BioCentury | Mar 16, 2021
Deals

March 15 Quick Takes: Canada’s CPP leads insitro’s $400M series C; plus Bicara, Aveo, Gilead-Merck and more

...that no longer respond to standard-of-care treatments. Its CEO, Claire Mazumdar, has prior experience at Rheos Medicines Inc....
BioCentury | Jan 8, 2020
Company News

Management tracks: Fred Hutch taps BMS CSO Lynch; plus GSK, Rubius, Provention, Antengene, Revitope, Compugen, Wellington, Adamas, Arcturus and Turnstone

...hired Laurence Turka as CSO, a new position. He co-founded and served as CSO of Rheos Medicines Inc....
BioCentury | Jan 4, 2020
Emerging Company Profile

Rheos: applying immune cell reprogramming to autoimmunity

...to attract its first major deal less than two years after launch. On Dec. 19, Rheos Medicines Inc....
...to systematically uncover the physiological links between metabolism of immune cells and disease.” Lauren Martz, Senior Editor Rheos Medicines Inc. AutoImmune...
BioCentury | Dec 19, 2019
Company News

Rheos spins immunometabolism platform into deal with Roche

...the partners may share worldwide development and U.S. commercialization rights to certain products. Lauren Martz, Associate Editor Rheos Medicines Inc. AutoImmune...
BioCentury | Oct 23, 2019
Company News

Management tracks: Amgen’s Meline retiring; plus BlackThorn, Rheos, Novartis, Kintai, Myriad, Avrobio, Oncorus, Moberg, Achilles and Aerpio

...Inc. (NASDAQ:TBPH). BlackThorn is a computational sciences company developing therapies for neurobehavioral disorders. Immunometabolism company Rheos Medicines Inc....
...ocular disease company has begun to explore strategic alternatives, including a possible sale. BioCentury Staff BlackThorn Therapeutics Inc. Rheos Medicines Inc. Kintai...
BioCentury | Oct 10, 2018
Company News

Management tracks: Hamburg joins Alnylam board

...Curatolo was head of commercial U.S. at NLS Pharma Group (Stans, Switzerland). Cellular metabolism company Rheos Medicines Inc....
BioCentury | Sep 6, 2018
Company News

Management tracks: Rheos, Aileron

...Immunometabolism company Rheos Medicines Inc. (Cambridge, Mass.) hired Sanjay Keswani as CEO. He was SVP and global head...
BioCentury | Apr 26, 2018
Targets & Mechanisms

Raising metabolism

...Management to develop glutamine antagonists to treat cancer. Two days later, Third Rock Ventures brought Rheos Medicines Inc....
...Ecto-5'-nucleotidase (CD73; NT5E) Preclin Ideaya Biosciences Inc. IDO Aryl hydrocarbon receptor (AHR) Preclin $140 2015 Rheos Medicines Inc....
...NASDAQ:INCY), Wilmington, Del. Kyn Therapeutics Inc., Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Rheos Medicines Inc....
BioCentury | Mar 23, 2018
Financial News

Third Rock launches immuno-metabolism company Rheos

...Immuno-metabolism company Rheos Medicines Inc. (Cambridge, Mass.) emerged from stealth mode with a $60 million series A round...
...transcriptional and metabolomic profiling data sets derived from human immune cell samples. Rheos Medicines Inc., Cambridge, Mass. Chris Lieu Rheos Medicines Inc....
BioCentury | Mar 22, 2018
Finance

Immune precision

...Third Rock Ventures is taking a page from cancer and Orphan diseases by launching Rheos Medicines Inc. to...
...of its companies when they go public (see BioCentury, Jan. 25, 2016) . Chris Lieu, Staff Writer Rheos Medicines Inc. Third...
Items per page:
1 - 10 of 11